FindTrial
Sign In

An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00329095
Enrollment
60
Registered
2006-05-24
Start date
2005-12-31
Completion date
2006-04-30
Last updated
2006-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Ocular Hypertension

Keywords

Glaucoma, Compliance

Brief summary

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Detailed description

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Interventions

DRUGtravoprost, latanoprost, or bimatoprost
DRUGAdditional ocular hypotensive medication

Sponsors

Robin, Alan L., M.D.
Lead SponsorINDIV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Currently using one or two topical ocular hypotensive medications

Exclusion criteria

* Hypersensitivity to any component of medication

Design outcomes

Primary

MeasureTime frame
Compliance.—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026